Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Talazoparib + Telaglenastat|
CB-839 binds to and inhibits glutaminase, preventing the conversion of glutamine to glutamate, which results in a decrease in cell proliferation (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Talazoparib||Talzenna||BMN673||PARP Inhibitor (Pan) 25||Talzenna (talazoparib) is an inhibitor of PARP1 and PARP2, which prevents the DNA repair of single strand DNA breaks, thus causing the accumulation of DNA strand breaks, genomic instability and apoptosis, and leads to lethality in homologous recombination repair deficient cells (PMID: 28242752). Talzenna (talazoparib) is FDA approved for use in patients with ERBB2 (HER2)-negative breast cancer harboring deleterious or suspected deleterious germline BRCA mutations (FDA.gov).|
|Telaglenastat||CB-839||Glutaminase Inhibitor 3||Telaglenastat (CB-839) binds to and inhibits glutaminase, preventing the conversion of glutamine to glutamate, which results in a decrease in cell proliferation (PMID: 31980651).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04824937||Phase II||Talazoparib + Telaglenastat||Telaglenastat + Talazoparib In Prostate Cancer||Not yet recruiting||USA||0|
|NCT03875313||Phase Ib/II||Talazoparib + Telaglenastat||Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors||Terminated||USA||0|